Eli Lilly has signed a new research ... its capabilities in artificial intelligence (AI)-driven drug development. The agreement covers up to two antibody programmes, with BigHat responsible for the ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly has signed ... artificial intelligence (AI)-driven drug development. The agreement covers up to two antibody programmes, with BigHat responsible for the design and engineering of ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

BigHat Biosciences, a biotechnology company, has entered a strategic collaboration with Eli Lilly and Company.

Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

California-based Creyon Bio has announced a global licensing and multi-target research collaboration with US pharma major Eli ...

April 25 (Reuters) - Eli Lilly (LLY.N), opens new tab has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug ... Huawei's growing AI capabilities ...

As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets on time scales ...

Creyon Bio, Inc. (Creyon) announced a global licensing and multi-target research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of novel ...

Eli Lilly (LLY) shares surge after data ... The trial is one of several that Lilly is running to test the drug, called orforglipron, in diabetes, obesity and other related conditions like sleep ...